

**UNITED STATES DEPARTMENT OF COMMERCE****Patent and Trademark Office**Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

(CD)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/160,977 09/25/98 SUNKARA

S

HM12/0524

HOECHST MARION ROUSSEL INC  
2110 EAST GALBRAITH ROAD  
P O BOX 15300  
CINCINNATI OH 45215-6300

EXAMINER

GOLDBERG, J

ART UNIT	PAPER NUMBER
----------	--------------

1614

6

DATE MAILED:

05/24/00

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

<b>Office Action Summary</b>	Application No. <b>09/160,977</b>	Applicant(s) <b>Sunkara</b>
	Examiner <b>Jerome D. Goldberg</b>	Group Art Unit <b>1614</b>

Responsive to communication(s) filed on Apr 3, 2000.

This action is **FINAL**.

Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 3 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

#### Disposition of Claims

Claim(s) 1-12 is/are pending in the application.

Of the above, claim(s) 4, 5, 9, and 10 is/are withdrawn from consideration.

Claim(s) \_\_\_\_\_ is/are allowed.

Claim(s) 1-3, 6-8, 11, and 12 is/are rejected.

Claim(s) \_\_\_\_\_ is/are objected to.

Claims \_\_\_\_\_ are subject to restriction or election requirement.

#### Application Papers

See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.

The proposed drawing correction, filed on \_\_\_\_\_ is  approved  disapproved.

The specification is objected to by the Examiner.

The oath or declaration is objected to by the Examiner.

#### Priority under 35 U.S.C. § 119

Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

All  Some\*  None of the CERTIFIED copies of the priority documents have been received.

received in Application No. (Series Code/Serial Number) \_\_\_\_\_.

received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\*Certified copies not received: \_\_\_\_\_.

Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

#### Attachment(s)

Notice of References Cited, PTO-892

Information Disclosure Statement(s), PTO-1449, Paper No(s). \_\_\_\_\_

Interview Summary, PTO-413

Notice of Draftsperson's Patent Drawing Review, PTO-948

Notice of Informal Patent Application, PTO-152

--- SEE OFFICE ACTION ON THE FOLLOWING PAGES ---

Art Unit: 1614

Claims 4, 5, 9 and 10 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b) as being drawn to a non -elected invention. Election was made with traverse in Paper No. 4. Applicant's remarks are noted but the other synergistic combination will support separate patents. Applicant elected the synergistic combination of cytarabine and (E)-2'- deoxy-2'-fluoromethylidene cytidine with traverse in Paper No. 4. The claims are still being examined as they read on the elected invention.

Claims 1-3 and 8 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the specific S-phase or M-phase specific agent" and "neoplastic disease state. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims. The term "a S-phase or M-phase specific agent" in claims 1-3 and 8 and "neoplastic disease state" in claims 1-3 and 8 lack clear exemplary support in the specification as filed.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-3, 6-8, 11 and 12 are rejected under 35 U.S.C. 103(a) as being unpatentable over the McCarthy et al. reference of record taken with the Carter et al. reference of record.

Art Unit: 1614

The references disclose applicant's ingredients alone for treating cancer. In view of this, one skilled in the art would be motivated to combine two known anticancer agents for their additive effects. Claims directed to the combination with the synergistic proportions of record would overcome this rejection.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Goldberg, whose telephone number is (703) 308-4606. The examiner can normally be reached on Monday through Friday from 9:00 a.m. to 3:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Cintins, can be reached on (703) 308-4725. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

J. Goldberg:jmr

May 17, 2000



JEROME D. GOLDBERG  
PRIMARY EXAMINER  
GROUP 1200